ScreenerHero

IMVTImmunovant, Inc.

NAS · US · Healthcare · Biotechnology · immunovant.com
44.37USD-1.31%Mkt Cap: 9.16B $P/E: —

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap9.16B $
Enterprise Value8.36B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-505.61M $
Revenue/Share—
Last Price44.37 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees315
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.74
PEG—
EV/EBITDA-14.79
EV/Revenue—
P/S—
P/B12.44
EPS (TTM)-2.77
EPS (Forward)-2.50
52W Range
14.4797% of range45.35
52W High45.35 USD
52W Low14.47 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.30%
ROA-52.83%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-407.31M $
CapEx (TTM)8.00K $
FCF Margin—
FCF Yield-2.60%
Net Debt-797.80M $
Net Debt/EBITDA1.41
Balance Sheet
Debt/Equity0.00
Current Ratio7.27
Quick Ratio6.82
Book Value/Sh3.565 USD
Cash/Share3.862 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.88 USD
Upside (mean)+7.9%
Target Range24.00 USD – 66.00 USD
$24.00+7.9% to mean$66.00
# Analysts16
Ownership
Shares Out.206.55M
Float91.48M
Insiders56.02%
Institutions53.97%
Short Interest
Short Ratio16.3d
Short % Float17.83%
Short % Out.7.93%
Shares Short16.38M
Short (prev mo.)17.99M
Technical
SMA 5039.01 (+13.7%)
SMA 20029.56 (+50.1%)
Beta0.81
S&P 52W Chg18.16%
Avg Vol (30d)959.98K
Avg Vol (10d)1.23M
Technical Indicators
RSI (14)70.1
MACD1.5089
MACD Signal1.1101
MACD Hist.+0.3989
BB Upper44.53 USD
BB Middle40.57 USD
BB Lower36.61 USD
BB Width19.52%
ATR (14)1.529 USD
Vol Ratio (20d)0.84x